Phenethanolamine derivatives for treatment of respiratory diseases
AssigneeGlaxo Group Limited
InventorsKeith Biggadike, Diane Mary Coe, Dean David Edney, Stephen Barry Guntrip, Abigail Halton, Brian Edgar Looker, Michael John Monteith, Rebecca Jane Moore, Rajnikant Patel, Panayiotis Alexandrou Procopiou
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.
Claims15
3-(3-{[7-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}-amino)heptyl]oxy}propyl)benzenesulfonamide, or a salt or solvate thereof.
A combination comprising 3-(3-{[7- ({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}-amino)heptyl]oxy}propyl)benzenessulfonamide, or a salt or solvate thereof, and 6α, 9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbonthioic acid S-fluoromethyl ester.
3-(3-{[7-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}-amino)heptyl]oxy}propyl)benzenesulfonamide (E)-3-(napthalen-2-yl)-2-propenoate.
A combination comprising 3-(3-{[7-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}-amino)heptyl]oxy}propyl)benzenesulfonamide (E)-3-(napthalen-2-yl)-2-propenoate and 6α, 9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbonthioic acid S-fluoromethyl ester.
Dependencies are inferred from the claim text.